Leonard H Wexler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7527747/publications.pdf

Version: 2024-02-01

43 papers

6,698 citations

236925 25 h-index 276875 41 g-index

43 all docs

43 docs citations

times ranked

43

12098 citing authors

#	Article	IF	CITATIONS
1	Tumour exosome integrins determine organotropic metastasis. Nature, 2015, 527, 329-335.	27.8	3,688
2	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell, 2020, 182, 1044-1061.e18.	28.9	691
3	Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nature Medicine, 2019, 25, 767-775.	30.7	282
4	Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clinical Cancer Research, 2016, 22, 1364-1370.	7.0	251
5	BCOR-CCNB3 Fusion Positive Sarcomas. American Journal of Surgical Pathology, 2018, 42, 604-615.	3.7	207
6	A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nature Genetics, 2014, 46, 595-600.	21.4	152
7	MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification. Modern Pathology, 2019, 32, 27-36.	5.5	126
8	Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors., 1996, 78, 901-911.		112
9	Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre–metastatic Niche. Cancer Research, 2016, 76, 1335-1347.	0.9	112
10	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nature Cancer, 2021, 2, 357-365.	13.2	74
11	A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. Pediatric Blood and Cancer, 2017, 64, e26409.	1.5	66
12	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nature Communications, $2022,13,.$	12.8	63
13	Predicting Outcome in Patients with Rhabdomyosarcoma: Role of [18F]Fluorodeoxyglucose Positron Emission Tomography. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1136-1142.	0.8	61
14	Rhabdomyosarcoma: Current Challenges and Their Implications for Developing Therapies. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a025650-a025650.	6.2	60
15	Insights into pediatric rhabdomyosarcoma research: Challenges and goals. Pediatric Blood and Cancer, 2019, 66, e27869.	1.5	57
16	NTRK3 overexpression in undifferentiated sarcomas with YWHAE and BCOR genetic alterations. Modern Pathology, 2020, 33, 1341-1349.	5 . 5	53
17	Positron Emission Tomography (PET) Evaluation After Initial Chemotherapy and Radiation Therapy Predicts Local Control in Rhabdomyosarcoma. International Journal of Radiation Oncology Biology Physics, 2012, 84, 996-1002.	0.8	49
18	Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors. Frontiers in Oncology, 2019, 9, 108.	2.8	49

#	Article	lF	Citations
19	Jaw in a Day. Journal of Craniofacial Surgery, 2016, 27, 2101-2104.	0.7	48
20	Late Toxicities of Intensityâ€Modulated Radiation Therapy for Head and Neck Rhabdomyosarcoma. Pediatric Blood and Cancer, 2016, 63, 1608-1614.	1.5	46
21	Plasma DNA-Based Molecular Diagnosis, Prognostication, and Monitoring of Patients With EWSR1 Fusion-Positive Sarcomas. JCO Precision Oncology, 2017, 2017, 1-11.	3.0	36
22	A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1 -mutant sclerosing are associated with unfavorable outcome. Oral Oncology, 2016, 61, 89-97.	1.5	32
23	20-Year Experience With Intraoperative High-Dose-Rate Brachytherapy for Pediatric Sarcoma: Outcomes, Toxicity, and Practice Recommendations. International Journal of Radiation Oncology Biology Physics, 2014, 90, 362-368.	0.8	31
24	Undifferentiated round cell sarcoma with BCOR internal tandem duplications (ITD) or YWHAE fusions: a clinicopathologic and molecular study. Modern Pathology, 2020, 33, 1669-1677.	5. 5	29
25	Combined modality treatment of Ewing's sarcoma of the maxilla. Head and Neck, 2003, 25, 168-172.	2.0	28
26	Morbidity and mortality after treatment of Ewing sarcoma: A singleâ€institution experience. Pediatric Blood and Cancer, 2017, 64, e26562.	1.5	27
27	Central nervous system relapse of rhabdomyosarcoma. Pediatric Blood and Cancer, 2018, 65, e26710.	1.5	27
28	Long-term effect of chemotherapy–intensity-modulated radiation therapy (chemo-IMRT) on dentofacial development in head and neck rhabdomyosarcoma patients. Pediatric Hematology and Oncology, 2016, 33, 383-392.	0.8	25
29	Clinical and molecular heterogeneity of head and neck spindle cell and sclerosing rhabdomyosarcoma. Oral Oncology, 2016, 58, e6-e11.	1.5	23
30	Pediatric rhabdomyosarcoma with bone marrow metastasis. Pediatric Blood and Cancer, 2020, 67, e28219.	1.5	22
31	Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Desmoplastic Small Round Cell Tumor. Sarcoma, 2015, 2015, 1-9.	1.3	21
32	Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer. JAMA Dermatology, 2020, 156, 963.	4.1	20
33	Patterns of Failure for Rhabdomyosarcoma of the Perineal and Perianal Region. International Journal of Radiation Oncology Biology Physics, 2014, 89, 82-87.	0.8	19
34	Paratesticular rhabdomyosarcoma: Importance of initial therapy. Journal of Pediatric Surgery, 2017, 52, 304-308.	1.6	17
35	Second cancer risk in childhood cancer survivors treated with intensityâ€modulated radiation therapy (IMRT). Pediatric Blood and Cancer, 2015, 62, 311-316.	1.5	16
36	Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide. International Journal of Radiation Oncology Biology Physics, 2019, 103, 1151-1157.	0.8	14

3

#	Article	IF	CITATIONS
37	Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor. Molecular Cancer Research, 2021, 19, 1146-1155.	3.4	14
38	A singleâ€enter experience with undifferentiated embryonal sarcoma of the liver. Pediatric Blood and Cancer, 2016, 63, 2246-2248.	1.5	13
39	Myxoid pleomorphic liposarcoma is distinguished from other liposarcomas by widespread loss of heterozygosity and significantly worse overall survival: a genomic and clinicopathologic study. Modern Pathology, 2022, 35, 1644-1655.	5 . 5	12
40	Metastatic Rhabdomyosarcoma: Still Room for Improvement. Journal of Clinical Oncology, 2016, 34, 105-106.	1.6	11
41	Clinicopathologic and survival correlates of embryonal rhabdomyosarcoma driven by <scp><i>RAS</i></scp> / <scp>/<scp>/<scp>/<scp>/<scp> mutations. Genes Chromosomes and Cancer, 2022, 61, 131-137.</scp></scp></scp></scp></scp>	2.8	8
42	Novel intraoperative radiotherapy utilizing prefabricated custom three-dimensionally printed high-dose-rate applicators. Brachytherapy, 2019, 18, 277-284.	0.5	6
43	When treatment does not work: failure to understand failure. Lancet Oncology, The, 2018, 19, 1004-1006.	10.7	0